Kliinisen lääketutkiuksen vaikutukset yliopistosairaalassa by Sjölund, Kristian
Aalto University 
School of Science 
Degree programme in Industrial Engineering and Management 
 
 
 
 
Kristian Sjölund 
 
Assessing the impact of sponsored clinical trials in a 
university hospital 
 
 
 
 
 
Master’s thesis 
Espoo, 21.10.2019 
 
 
 
 
 
Supervisor:  Professor Paul Lillrank 
Instructor:  Assistant professor Paulus Torkki 
  
  
ii 
AALTO UNIVERSITY 
School of Science                                                                                  ABSTRACT OF THE  
Master’s Programme in Industrial Engineering and Management         MASTER´S THESIS 
  
Author: 
Kristian Sjölund                                                                                             
Title of the thesis:  
Assessing the impact of sponsored clinical trials in a university hospital 
Number of pages: 
48+9 
Date:  
8.10.2019 
Major: 
Operations and Service Management, SCI3049 
Supervisor:  
Paul Lillrank 
Thesis advisors: 
Paulus Torkki  
Clinical trials are the normal path for new drugs to enter the market. They are also 
a major economic factor both for the healthcare systems in which they are carried 
out, as well as for the individual hospitals. However, limited study exists on the 
total effect they have in hospitals. 
 
This thesis studied the costs and benefits of conducting clinical trials in a University 
hospital. The study combined qualitative analysis through a questionnaire 
conducted with all staff members related to clinical trials as well as quantitative 
analysis of the bookkeeping data and drug cost data. All the studies of Helsinki 
University Hospital’s oncology and hematology wards from 2017 and 2018 were 
analyzed. 
 
The main finding of this study is that clinical trials are highly beneficial, and they 
carry many benefits in addition to the drug cost avoidance that has been identified 
in previous literature. Clinical trials enhance the quality of care patients receive, as 
well as can help heighten work motivation. Drug cost avoidance has been 
somewhat overestimated in the past, due to many modern drugs being highly 
expensive and clinical trials being focused on last-line treatments. As most of the 
patients would no longer receive expensive drugs as part of standard protocol, the 
savings have been overestimated in previous studies.  
 
Future research should focus on identifying and quantifying in more detail the 
qualitative benefits clinical trials have on staff performing them, as well as 
identifying efficient managerial actions that can enhance those benefits.  
Keywords:  
Clinical trial costs,  
drug cost avoidance, clinical trial 
Publishing language: 
English 
 
 
  
iii 
AALTO-YLIOPISTO 
Perustieteiden korkeakoulu                                                                          DIPLOMITYÖN  
Tuotantotalouden tutkinto-ohjelma                                                                 TIIVISTELMÄ 
  
  
Tekijä: 
Kristian Sjölund                                                                                             
Työn otsikko:  
Kliinisen lääketutkiuksen vaikutukset yliopistosairaalassa 
Sivumäärä: 
48+9 
Päiväys:  
8.10.2019 
Pääaine: 
Operations and Service Management,  SCI3049 
Valvoja:  
Paul Lillrank 
Ohjaaja: 
Paulus Torkki  
Kliininen lääketutkimus on keskeinen vaihe uusien lääkkeiden matkaa 
markkinoille. Niillä on myös merkittävä taloudellinen vaikutus niin sairaaloille, 
jotka niitä tekeävt, kuin myös terveydenhuoltojärjestelmälle yleisemmin. Tästä 
huolimatta niiden kokonaisvaikutuksia on tutkittu vain vähän kirjallisuudessa. 
 
Tässä tutkimuksessa tutkittiin kliinisten lääketutkimusten kokonaisvaikutusta 
yliopistosairaalassa. Aineistona olivat kaikki Helsingin Yliopistollisessa 
Keskussairaalassa vuosina 2017 ja 2018 tehdyt kliiniset tutkimukset. Niiden osalta 
yhdisteltiin kvalitatiivista tutkimusta, joka tehtiin kyselyllä henkilöstölle, sekä 
kvantitaviista analyysiä kirjanpidosta. 
 
Tutkimuksessa havaittiin että kliinisellä lääketutkimuksella on kokonaisuutena 
suuri positiivinen vaikutus. Erityisesti aiemmin kirjallisuudessa havaitun 
lääkesäästön oheen tunnistettiin useita vaikutuksia, joista on hyötyä sairaalalle. 
Näihin kuuluvat esimerkiksi työhyvinvoinnin lisääntyminen sekä hoidon laadun 
paraneminen. Tutkimuksessa havaittiin myös, että aiemmat selvitykset ovat 
yliarvioineet lääkekustannussäästön suuruutta. Tämä johtuu pitkälti siitä, että 
nykyisin tutkittavat lääkkeet ovat viimeisen linjan lääkkeitä, ja niitä saavat potilaat 
eivät saisi normaalihoidon piirissä muuta kuin palliatiivista hoitoa. 
 
Jatkotutkimuksen tulisi keskittyä tunnistamaan ja kavantifioimaan tarkemmin se 
vaikutus, joka kliinisillä lääketutkimuksilla on, sillä tässä tutkimuksessa ei kyetty 
erottelemaan näitä vaikutuksia kokonaisuudesta. Toinen jatkotutkimuksen aihe 
on sellaiset toimenpiteet, joilla yliopistosairaala voisi lisätä kliinisen 
lääketutkimuksen positiivisia vaikutuksia.  
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1 Introduction 
Over the past two decades vast amounts of new drugs have entered the market, and 
the types of diseases that are treatable with drugs have increased. There are, for 
example, many types of cancers which are today treatable with drugs that extend the 
expected lifespan, that were not treatable at all just 20 years ago. At the same time, 
immense amounts of money are used for investigational drugs, with U.S. spending 
increasing by 27% to $121.8 billion between 2013 and 2017 (Research America, 2018).  
This spending is both vital for future developments in medicine as well as a major 
economic factor for developed countries, where the research is carried out. This has 
led to competition between countries on where clinical trials are performed. However, 
previous research into the total effects that clinical trials have in hospitals is limited. In 
order to give decisionmakers at both national level and in individual hospitals more 
knowledge about the total effects of clinical trials to base decisions on, this study was 
conducted. 
1.1 Background 
The road from an investigational drug to the market is long, with three main phases of 
clinical trials. The total duration of the process is up to 6 years (FDA, 2019). Phase 1 
means, usually but not always, testing the drug on healthy individuals to find unwanted 
side-effects. Phase 2 means giving the drug to patients with the disease the drug should 
have an effect on in order to observe if it has the desired effect. Phase 3 is comparing 
the treatment to standard care in order to find out if the drug is more effective at 
treating the disease than existing alternatives. (Cancer research UK, 2019).  
A large part of this process is clinical trials in university hospitals, as they are a 
required stepping stone for new drugs to enter the market through phases 2 and 3. 
These have both direct financial implications for the hospitals carrying out the research 
as well as indirect effects by, for example, giving earlier access to new, promising drugs 
(LaFleur et al., 2004). The impact these clinical trials have has been studied before, but 
often only from the perspective of drug cost avoidance. This study aims to set a context 
for the cost avoidance received from drugs by analyzing the total impact sponsored 
clinical trials have on a university hospital. 
While the total amount of investigational drugs has increased worldwide, there 
has been a relatively sharp decline in the amount of sponsored clinical trials in Finland 
from 268 in 2008 to a low of only 144 trials in 2017 (Fimea, 2018). The decline seems 
1.1 Background 
 
2 
to have stopped, with 150 trials in 2018 (Fimea, 2019) The reasons for this are 
unknown, but taking efforts to increase the number of clinical trials back to the level of 
2008 might prove to be a profitable investment for Finland and university hospitals in 
Finland. This study aims to give decisionmakers a tool for evaluating the potential 
effects of clinical trials in order to make more informed decisions about them in the 
future. 
Finland has also fallen behind in relation to other Nordic countries, with 
Denmark being a successful example of increasing the number of studies over the past 
decade (U.S. National Library of Medicine, 2019). Denmark has an active government, 
that has focused heavily on increasing the amount of scientific research in general, for 
example waiving fees from phase I clinical trials in order to increase their amount. 
Thanks to their efforts, Denmark has the highest number of clinical trials per capita in 
the world in 2017 (U.S. National Library of Medicine, 2019). Thus, there is no 
fundamental reason related to healthcare system or regulation that prevents Finland 
from gaining a similar position. 
Of the clinical trials carried out in Finland roughly 40% are phase 3, 25% phase 
2, 20% phase 4 and 15% phase 1 (Fimea, 2019). Of these this study focuses on phases 
2 and 3, as well as those phase 1 trials that are carried out in a similar fashion to phases 
2 and 3. In modern drug development the drugs are often ill-suited for traditional phase 
1 trials, as they have so sever effects giving them to healthy individuals would be 
unethical (Cancer research UK, 2019). Thus, phase 1 trials are essentially carried out in 
a similar manner as phase 2 trials, with differing focus points and goals. 
The total costs and benefits of clinical trials are an interesting area due to 
several factors. Most importantly, the amount of clinical trials performed at a hospital 
is highly influenced by not only the actions of that hospital, but by the government and 
how willing they are to encourage clinical trials in a country. Denmark has invested 
heavily into clinical trials, with much success (Ministry of foreign affairs of Denmark, 
2019). In order to persuade decisionmakers in Finland to invest in clinical trials a 
comprehensive look at the total benefits and costs involved is needed. 
One aspect of public discussion often focuses on the quality of studies 
conducted with a pharmaceutical company. It is a realistic concern: if conducting 
clinical trials is too beneficial there is a risk of hospitals being too eager to take them 
and bend the rules. Fraud and misconduct are also widespread in clinical research 
(Gupta, 2013). However, based on discussions with both pharmaceutical corporation 
and doctors, there is minimal risk of this on a systemic level as the integrity of everyone 
involved is at a very high level. Indeed, one could argue that highly monitored, 
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sponsored clinical trials are less subject to bias than less monitored, purely academic 
research. 
The study was conducted under Helsingin ja Uudenmaan sairaanhoitopiiri HUS, 
the public health care provider of Helsinki and Uusimaa. It is publicly funded and 
provides all levels of healthcare. Specifically, the study was conducted in Helsinki 
University Hospital, which provides tertiary care for citizens of southern Finland. It also 
has research and teaching duties and conducts large amounts of both sponsored and 
non-sponsored clinical research. 
1.2 Clinical trials 
Clinical trials are performed at all university hospitals in Finland as one of the core 
activities (Fimea, 2019). Clinical trials commonly last several years with several phases, 
and include three main activities for the hospitals involved. First, patient recruitment. 
Secondly, administering care. Lastly, measuring effects. 
Patient recruitment is the act of finding suitable patients for the clinical trial. 
This is often done in modern settings with the help of electronic patient records, as 
many new trials are for very specific subsets of patients and finding those is difficult.  
Administering care is the act of following the trial protocol to administer the 
care. Many trials include many treatment arms, in which patients receive different 
treatments that are assessed in relation to each other. In some cases the control 
treatment arm is a standard treatment, but it can also be placebo, especially for last 
line treatments that are given to terminally ill patients. Whether the care is 
administered as part of standard care or by specialized research nurses varies between 
trials. 
The measurement of the effects is often done all throughout the trial and 
revolves around gathering the data. Clinical research nurses are often in a critical role 
in this part, filling forms of adverse effects and other variables that are monitored. 
Clinical research nurses are specialized nurses that are trained to perform activities 
related to clinical trials, and must often fulfill criteria set by the medical company 
sponsoring the trials.  
Clinical trials are somewhat different from most activities in a hospital, as they 
can be organized in many different manners. There is no set division of labor, and 
nurses often conduct more activities than in standard care. The dimensions of clinical 
nurse activities and their definitions are shown below in figure 1. 
  
1.2 Clinical trials 
 
4 
Dimension Definition 
Clinical 
Practice 
 
 
 
 
 
Provision of nursing care, education, and support, using the nursing process, to 
participants in clinical research and their families and significant others. Care 
requirements are determined by the scope of study participation, the clinical 
condition of the patient, and the requirements and clinical effects of research 
procedures and data collection 
 
 
Study 
Management 
 
 
Management of clinical and research support activities in order to assure patient 
safety, address clinical needs and assure protocol integrity and accurate data 
collection 
 
Care 
Coordination 
and 
Continuity 
 
 
Coordination of research and clinical activities to meet clinical needs, complete 
study requirements and manage linkage with referring and primary care 
providers 
 
 
 
Human 
Subjects 
Protection 
 
 
Facilitation of informed participation by diverse participants in clinical research 
 
 
 
 
Contributing 
to the Science 
 
Contributions as a research team member to the development of new ideas for 
study, explorations of innovations arising for clinical research and application of 
clinical research findings to practice 
Figure 1 Dimensions of clinical nurse activities (Hastings et al., 2012) 
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1.3 Research questions 
Based on the literature review no comprehensive framework exists to assess the impact 
clinical trials have in a university hospital. Therefore, the main theoretical contribution 
of this work is forming a framework for future analysis of the financial impacts of 
sponsored clinical trials. So far, the view the academic literature has had has been 
focused on only some aspects of the question, and thus previous literature fails to give 
a complete answer. The two research questions formulated are shown below. 
 
1. How should the total costs and benefits of sponsored clinical trials be assessed 
in a university hospital? 
2. What are the total costs and benefits of sponsored clinical trials in the oncology 
and hematology departments of HUS Helsinki University Hospital? 
 
The research questions are deeply intertwined, with research question 2 being 
essentially an application of the findings of research question 1. The original task and 
question asked by HUS, the public health care provider of Helsinki and Uusimaa, was 
research question 2, but due to the lack of literature on the subject this study needed 
to develop a suitable framework for assessing the total costs and benefits. 
In this context total costs and benefits refer to all possible effects that clinical 
trials have, whether they are direct or indirect. It includes, but is not limited to, drug 
cost avoidance, clinical expertise, quality of care and employee satisfaction. The aim is 
to understand the area wholly, and not just through easily quantifiable measurements. 
Healthcare is a highly personnel-intensive field, and as such factors affecting employees 
are of high importance.  
1.4 Scope 
This study was carried out in only one university hospital, the Helsinki 
university hospitals. The factors creating the impact are the same in other hospitals 
within similar legislations and can be modified to function also in other legislations. 
However, the contracts university hospitals and sponsors have in other countries might 
vary, so the results of this study cannot be directly generalized to other countries 
without analysis of the differences between Finnish healthcare systems and those of 
that country. However, the results are in line with those calculated in, for example, New 
Zealand, which to some extent confirms that the impact is similar in differing 
legislations.  
1.4 Scope 
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The exact system of reimbursing drugs has a high impact on the exact cost 
saving. In the context of this study, any drug that does not need to be paid for is a cost 
savings. However, in for example an American setting, where insurance companies pay 
for the majority of drugs, this incentive might not exist in a similar fashion. 
Nevertheless, studies from the U.S. are usable as the same effect does exist, even if the 
benefactor is not the hospital directly.   
This study analyzed data gathered at the Hospital from 2012 to 2018. However, 
only 2017 and 2018 were available for the drug cost avoidance savings, and thus the 
scope was limited to only 2017 and 2018. Where data was available, the analysis was 
done 2012-2018, with only the results from 2017-2018 being included in the final totals. 
For example, overhead and laboratory costs were analyzed 2014-2018 as data was 
available for that period and analyzing a longer time period validated the way of 
analysis. 
This study is focused on phases 2 and 3 and only on sponsored clinical trials, as 
assessing the impact of non-sponsored clinical trial would require much additional work 
focused just on them. The studies being carried out by university hospitals without 
sponsors vary wildly and can last for decades. Thus, they need to be studied separately 
if some sort of assessment of their financial impact is desired. There have also been 
prior studies on their total effects, and as such they are not relevant for the scope of 
this study. While exploring the trials carried out at HUS, it was noted that hematology 
also carries out phase 1 trials which are in practice identical to phase 2 trials. This is due 
to the nature of the new drugs being developed, which is ill suited for the traditional 
phase 1 approach. Thus, those studies were also included. In effect, all clinical trials at 
oncology and hematology departments of HUS were included, as there were no phase 
4 trials in the data.  
This study is limited to only include oncology and hematology, the two major 
departments that treat cancers. These two departments, whose administrations are to 
an extent shared, generate the majority of all sponsored clinical trials, and an even 
larger portion of the drug costs due to the very high cost of highly specialized cancer 
drugs. Cancer drugs were the investigational drug in 45.1% of clinical trials in Finland in 
2018 (Fimea, 2019), and for this reason oncology and hematology are the most 
interesting specialties for clinical trial effect assessment.  However, the framework and 
results of this study are applicable in other specialties, as no part of the framework is 
specific to specialty. The analysis of indirect effects to employees was done using a 
questionnaire that also included rheumatology staff. This was done in order to increase 
the number of answers. Rheumatology was chosen because it conducts clinical trials in 
1.5 Structure 
 
7 
a similar manner to oncology and hematology departments, and thus the answers from 
staff in these three departments should be similar.  
1.5 Structure 
The study is structured around the original two research questions and discussion on 
the managerial implications that this study has. First, a literature review is performed, 
based on which the framework for assessing total costs and benefits is structured. After 
that, the framework is applied to the data collected in this study and those results are 
analyzed. Lastly, those findings are analyzed from a managerial point-of-view in order 
to give suggestions to HUS on areas of improvement in the future that would maximize 
the benefits of sponsored clinical trials. Additionally, points of improvement from other 
points-of-view are also considered, such as whether investments into investigational 
drug services on a national level might be profitable. 
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2 Literature review 
This study combines qualitative and quantitative analyses to form a complete picture 
of the impact sponsored clinical trial have on university hospitals. This requires careful 
literature review of not only previous studies on clinical trial costs, but also of studies 
concerning the effects clinical trials have on e.g. the quality of care. Of these, drug cost 
avoidance is the most researched topic, with high-quality research for benchmarking.  
However, in general there is only very limited study into the field. In order to widen the 
scope and understand how this study relates to prior research this literature review 
also includes studies that did not directly consider sponsored clinical trials. For example, 
studies about how clinical expertise develops by conducting research at hospitals is 
reviewed, as those findings are also applicable in a sponsored clinical trial setting.  
Due to the nature of clinical trials in the past 2 decades differing from those 
performed earlier, some articles were omitted. Results from studies published before 
2000 were not included, as the financing model of clinical trials has shifted as the drugs 
being investigated have evolved, and as such earlier results are not necessarily 
applicable in 2019.  
2.1 Total cost 
The total benefits and costs of sponsored clinical trials have not been extensively 
studied. However, studies have identified different factors affected by clinical trials, 
illustrated in table 1. This only includes those studies that directly explored clinical trial 
effects. Further research that is applicable includes research into the effects of 
academic research on personnel at hospitals, but due to the variance in their focuses 
they are analyzed individually later.   
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Table 1 Literature on the impact of clinical trials 
 
Drug cost avoidance is the most studied area, with oldest studies dating back 
to the 80s. As such, the issue is not new to academic literature. However, no 
comprehensive framework for assessing the total cost effect of sponsored clinical trials 
exists. The study by Murphy (2011) had the most comprehensive framework, but had 
a very limited scope, and the final results were never published. Thus, there are no 
reliable results in prior academic literature about the total costs and benefits of 
sponsored clinical trials that we could use as a reference. Instead, the framework must 
be collected by analyzing all existing literature and synthetizing the factors identified in 
them into one comprehensive framework. 
 
2.1.1 Overhead costs 
Overhead costs in this context refer to the general overhead costs of acquiring clinical 
research agreements. This includes administrative work for creating budgets and 
invoicing, as well as lawyers and contract negotiations. These have a notable effect on 
the total cost, as they are costs that are incurred solely because clinical trials are 
performed, and they create no value for the patient. These have not been studied 
extensively, as they are essentially a managerial challenge. However, the cost-
effectiveness of clinical trials has been studied and can be used as a proxy: the higher 
the cost-effectiveness, the lower the overhead costs.  
Multi-country clinical trials have very wildly varying cost-effectiveness 
numbers in clinical trials (Willke et al., 1998). Thus, the overhead costs must vary, as 
the treatment issued is identical. There can be several explanations for this, but they 
can be divided into country-specific and hospital-specific factors. In any case, when 
discussing costs, it is clear that overhead costs must be included in the framework. 
 
Drug cost 
avoidance 
Overhead 
costs 
Laboratory 
and related 
costs 
Patient care 
quality 
Murphy, Lyn 2011 x 
 
x x 
LaFleur et al. 2004 x x 
  
McDonagh et al. 2000 x x 
  
Bredin et al. 2010 x    
Braunholtz et al. 2001 
  
x 
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Overhead costs often have minimal direct financial impact, as they are costs 
that the sponsors pay. However, minimizing overhead leads to more effective trials, 
which in turn leads to more trials. This is why overhead costs are important despite not 
having a direct financial impact on the short run.  
Patient recruitment speed and quality is a major factor for the overall cost-
effectiveness of the clinical trial. Failing to recruit enough patients can delay the whole 
trial if conducting a multicenter trial – as most modern trials are – and as such can lead 
to major costs for the medical company. Studies have found limited difference between 
nurse and doctor recruitment efficiency in cancer studies, but nurses are more cost-
effective due to the lower hourly cost of nurses (Donovan et al., 2003).  
2.1.2 Laboratory and related costs 
Clinical trials often include laboratory tests or imaging, which can sometimes be utilized 
as part of the care. This creates cost savings, as those laboratory and imaging costs are 
covered by the sponsor of the clinical trial. Thus, estimating the cost savings achieved 
here can have a major effect on some research. As an example, a clinical trial that 
requires constant monitoring of blood values for a patient for whom those markers 
would be monitored as part of standard care. In this situation the laboratory costs are 
paid for, at least in part, by the sponsoring medical company, thereby creating cost 
savings. 
The study of Murphy et al. (2011) included this factor in the plans, but the 
results were never published. Thus, no reference exists as a starting point for the 
framework. As the total values of laboratory and imaging services at HUS are hard to 
collect due to being under varying sections in bookkeeping it is also relatively difficult 
to assess how large this effect could be. However, in relation to drugs and drug 
administering costs, they are not high and as such we could expect that the effect 
laboratory and imaging have in clinical trials is relatively small. 
2.1.3 Patient care 
The change in the quality of patient care has been researched extensively. There is 
evidence of a trial effect, i.e. that participating in a clinical trial benefits the patient 
(Braunholtz, Edwards, & Lilford, 2001). What causes this is subject to discussion, but in 
the scope of this study the mere existence of such an effect means we can take it as a 
given that the effect clinical trials have on patient care is either positive or nonexistent. 
Thus, our model can ignore this, leaving it for future studies, as it is very difficult to 
2.2 Drug cost avoidance 
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quantify and is very subjective and dependent on multiple variables such as quality of 
the physician administering care.  
2.2 Drug cost avoidance 
Drug cost avoidance have been studied somewhat extensively in academic literature. 
However, the methodology applied varies, with some estimating drug cost avoidance 
based on the actual drugs used, and some based on estimates of what would have been 
the cost of standard care. The timespans over which the costs have been analyzed have 
also often been relatively short, often due to lack of data. 
In 1996-1997 McDonagh et al. did the first notable study on the cost savings of 
investigational drug services, IDS for short. They found that IDS reduced costs by $1 
million and $1.6 million in two separate institutions (McDonagh, Miller, & Naden, 
2000). However, their study is somewhat outdated, and was solely focused on whether 
IDS is beneficial to hospitals in general. They do state that there are intangible benefits, 
such as improved patient safety as well as goodwill and collaboration, but how large 
these are or whether they are a result of doing clinical trials or of the way a hospital 
organizes it is left open. It should also be noted that this study is from the U.S., where 
drug compensation systems differ heavily from those used in Finnish hospitals. Thus, 
its results are not very applicable beyond the conclusion that investigational drugs have 
a beneficial effect on the costs of drugs in hospitals. 
LaFleur, Tyler & Sharma found in their study that investigational drug services 
accounted for substantial reductions in drug costs. Their methodology was based on 
two fiscal years’ of data and focused heavily on drug costs. They included drug 
dispensing costs and estimated contract acquisition costs, but they did not assess other, 
non-drug related impacts. Their results found that the 107 investigational studies 
accounted for roughly $2.5 million of drug cost avoidance annualized. However, the 
actual realized drug cost avoidance varied highly, being under $2 million one year and 
over $3 million in the last year. (LaFleur, Tyler, & Sharma, 2004) 
What is noteworthy in the study of LaFleur et al. is the high variance in cost 
reductions between specialties. This reflects the fact that the timespan of only 2 years 
is short for studying cost reductions when singular drugs might cause very high 
fluctuations in cost savings. On the other hand, this is a natural consequence of the very 
high cost of modern cancer drugs. As the treatments are highly expensive, singular trials 
have a major impact on the total value of drug savings even if the number of clinical 
trials does not very much. 
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The cost savings found in these studies are in line with each other, and thus we 
should expect our study to find similar results for the drug cost avoidance. However, as 
clinical research spending has increased and the drug spending in healthcare has grown, 
we expect the numbers of 2012-2018 to be somewhat higher than in earlier studies.  
However, there is one study with quite differing results. This study only 
released preliminary results, which only included two trials over a longer time span. 
Those trials actually had a negative cost saving result for the university hospital 
(Murphy, n.d.). If a patient has a response to the trial drug, they are given it also after 
the trial, naturally. However, the drugs are free of cost only for the duration of the 
study, and continuing treatment with the trial drug after the trial has ended might be 
more expensive than standard care would have been. What this study highlights are 
that not all clinical trials are beneficial, and care must be taken that the picture we have 
of clinical trials is not overly positive. It is indeed possible that a trial has negative results 
for the cashflows of the hospital as well as for the patient herself. Investigational drugs 
are investigational because there is limited scientific proof of their effectiveness, and 
this must be kept in mind when discussing the total costs of investigational drugs. The 
process put in place for new drugs to enter the market has been developed for a reason.  
There have been estimates in HUS and in Finland on the size of drug cost 
avoidance due to sponsored clinical trials. The most recent and comprehensive is a non-
academic study by Karma (2012). Despite not being peer-reviewed, it is well written, 
and the results are supported by academic research. The study cites drug cost 
avoidance at a value of €15 million in HUS in 2010 (Karma, 2012). However, this number 
has two main issues. Firstly, it is outdated as the amount of clinical trials in Finland has 
declined sharply since 2010 and the types of clinical trials might also have shifted 
heavily since then. Secondly, it is an estimate from the medical industry in Finland, and 
the original source is not well available. Based on interviews conducted during this 
study it is safe to assume that it is purely based on the value of drugs provided free of 
cost to HUS as part of clinical trials, and as such is somewhat inaccurate. 
2.3 Factors not directly linked to sponsored clinical trials 
Academic literature has considered other impacts of clinical trials, but not in the 
context of total cost analysis and they have not been analyzed from a monetary 
perspective. However, when creating the framework in this study these factors were 
considered, as they have a major impact on the total benefits. 
Research in general has been studied previously, often being coupled with 
teaching in order to calculate how much university hospitals should be compensated 
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due to their responsibilities including these activities. The total cost of research and 
teaching in University hospitals in Finland was between €78 million and €104 million in 
2002-2006, of which slightly under half consisted of research. The study used a 
statistical approach to estimate the amounts, as they are practically impossible to 
calculate otherwise. (Linna, 2006). 
This estimate gives a ballpark figure on what the results of this study should 
be. However, it includes many activities not included in this study, and thus the 
validation must be done with care. It is very difficult to say which part of this number is 
related to clinical trials, as only a small portion of those activities are relevant. 
According to interviews conducted in this study, however, there is some overlap in 
managing research as both sponsored clinical trials as well as academic research often 
goes through HUCH.  
When discussing benefits, one major factor that cannot be ignored is employee 
well-being, and through it, employee turnover rate. The cost of replacing a faculty 
member ranges from $115,554 to $587,125 based on specialty (Schloss et al., 2009), 
and overall medical staff turnover comprises 3.4-5.8 percent of the total operating 
budget (Waldman et al., 2004). Although these results are from the U.S., we can safely 
assume that the costs of turnover are high also in Finland. Although the salaries and 
income models differ, it is clear that turnover is a major expense. Considering that HUS 
employs thousands of nurses and doctors, the effect of clinical trials on employee 
turnover and recruitment should be assessed. As HUS has an operating budget of 
€2 277 million in 2019, employee turnover comprises between €77.8 million and €132 
million. The major driver of this cost is nurse turnover (Waldman et al., 2004). 
Indeed, nurses have a relatively high turnover globally, and most member 
states of the WHO have reported nurse resource difficulties (Kingma, 2001). Job 
satisfaction is a major factor in nurses’ turnover, and job involvement, autonomy, 
collaboration with medical performance have been found to have a correlation with 
job satisfaction (H. Lu et al., 2005). Clinical trial involvement could thus increase job 
satisfaction, leading to cost savings through lower turnover. However, there is not yet 
enough literature to understand the relative importance of different factors linked to 
nurse commitment, and thus it is hard to estimate the magnitude clinical trials might 
have on nurse turnover (Lu, Yang & While, 2005).   
A study performed at HUS found a strong link between research and clinical 
expertise. Käypä hoito -recommendations, a national system of treatment protocols, 
was heavily influenced by the research performed at HUS, and this effect had a higher 
effect on clinical practices than the direct findings of research (Karma, 2012). Similarly 
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it has been found that most nurses report participating in clinical trials as an important 
factor for improving standards of care (Burnett et al., 2001).  
We can assume that this effect exists in clinical trials, and not only academic 
research, and should be considered in a comprehensive framework. However, this 
aspect has two challenges in the context of this study. Firstly, it is very difficult to 
measure in any fashion, as the effect of different factors related to clinical expertise 
and clinical practices are hard to distinguish from each other. Secondly, the studies 
either did not focus on nurses or they were performed based on self-assessment. As 
clinical expertise is a complicated issue, relying on self-assessment is somewhat 
unreliable and thus care needs to be taken when assuming effects on quality of care. 
2.4 Clinical trial quality  
The quality of clinical trials is the main factor affecting the willingness of medical 
companies to continue co-operation with a university hospital according to the 
interviews with a medical company conducted in this study. Therefore, the factors 
affecting clinical trial quality are of interest for this study despite not having a direct 
effect on university hospitals. 
Quality is a multidimensional concept, which could relate to the design, 
conduct, and analysis of a trial, its clinical relevance, or quality of reporting (Jüni, 
Altman & Egger, 2001). However, only some of these aspects are influenced by the 
hospital conducting the trial. Clinical trial quality can be divided into internal and 
external validity. Internal validity means minimizing bias in clinical trials, such as 
selection bias and performance bias. External validity relates to reproducibility of the 
results, and includes patients, treatment regimens, setting and modalities of outcomes 
(Jüni, Altman & Egger, 2001). 
Of these the hospital has a clear effect on external validity factors. Essentially 
how well the university hospital delivers on the agreed upon tasks determines the 
quality of the university hospital for the clinical trial. The treatment regimen and 
conforming to the trial are of high importance. Internal validity factors are largely 
dependent on only the sponsor of the clinical trial, and as such they can be ignored 
from the point of view of the hospital. 
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3 Methodology 
In this chapter we develop the framework based on prior research that will be used to 
assess the costs and benefits of sponsored clinical trials. This framework is based on 
prior academic literature as well as the questionnaire that was used to assess the 
qualitative effects clinical trials have on personnel. The framework also incorporates 
areas that have not been previously considered, such as employee well-being, that have 
a major impact on the cost effect clinical trials have according to our research. 
3.1 Performance measurement 
In general measuring indirect effects is difficult, as there is no direct indicator of them. 
For direct costs, the pure monetary value can be analyzed, but indirect costs and 
benefits require a set of measurements. In order to combine these two types of effects 
a tool is required. In this study the framework utilizes an approach called Balanced 
Scorecard, which has four perspectives: Financial, customer, internal business and 
innovation and learning perspective (Kaplan & Norton, 1992). The total value of clinical 
trials is the sum of the impact that clinical trials have across all perspectives. In the case 
of hospitals, the customer perspective becomes the patient perspective, as Finnish 
healthcare is publicly funded.  
3.2 Theoretical framework 
The framework developed in this study is shown below in table 2. As we can see, a 
majority of the factors identified in this study are indirect, and relatively difficult to 
measure. This explains why those factors have been largely ignored in prior research, 
and simultaneously shows why their assessment is so important in order to understand 
the whole of the issue.  
The factors are divided into benefits and costs as well as into indirect and direct 
effects. Direct effects are all effects that cannot be directly measured in monetary 
value. Indirect effects include everything else, ranging from faster access to new 
treatments to employee well-being.  
This framework displays all the aspects that must be considered when 
assessing the total effect clinical trials have. Each of these factors has several further 
implications that need to be considered and require a measuring tool to be usable. 
Below each factor is analyzed in relation to the literature review and interviews carried 
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out at HUS. The table also displays the perspective of the balanced scorecard that each 
individual effect relates to. 
Table 2 Framework for analyzing total costs and benefits of sponsored clinical trials 
 
 
 
+Benefits Direct Perspectives 
 
 
Drug cost avoidance 
 
Financial 
 
Laboratory and imaging expenses 
 
 
Financial 
 
 
Monetary compensation 
 
Financial 
 
 Indirect  
 
Recruitment 
 
 
Innovation and learning, 
internal business 
 
Clinical expertise 
 
Innovation and learning, 
Internal business 
 Clinical practices Internal business, patient 
 
 
Employee well-being Internal business 
 
 
Trial effect Patient 
 Faster access to new treatments 
 
Patient 
-Costs 
 
Direct  
 
 
Overhead expenses Financial 
 
 
Indirect  
 
 
Employee well-being Internal business 
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3.2.1 Drug cost avoidance 
Drug cost avoidance is the major factor impacting direct financial benefits from 
sponsored clinical trials. It is mainly affected by two variables. Firstly, the amount of 
clinical trials carried out. This is largely uncontrollable in the short term for the hospital, 
but the quality of the research can over the long-term lead to an increase in the amount 
of research being carried out. Secondly, it is impacted by the cost of care given to 
patients that are not taking part in clinical trials. As the amount of drug cost avoided is 
based on the drug the patient would have received had they not participated in the trial 
there is considerable fluctuation in the exact amount saved.  Finally, using theoretical 
patients is inaccurate as it is very difficult to estimate the exact dosages each individual 
patient would have received. 
Measuring drug cost avoidance has one major decision that must be made: 
whether the prices used as a reference include discounts that the hospital gets via 
deals, or if standard prices are used. In order to increase transparency of the results, 
this study calculates both. As the deals and exact costs of drugs might change annually, 
using the prices HUS would have in 2018 for drugs received in e.g. 2017 might be 
inaccurate, and thus both values are needed. In 2017 and 2018 this price difference was 
roughly 10% of the total cost of drugs received free of charge. 
3.2.2 Laboratory and imaging expenses 
The number of laboratory tests and scans performed due to be a part of clinical trials 
that can also be utilized as part of standard care. This is a very difficult factor to 
estimate, as the tests carried out on patients in standard care can vary based on the 
doctor giving care. One possible method of estimating this factor would be to 
determine based on the clinical trial protocol the proportion of tests that are relevant 
for patient care for each clinical trial separately. Whether this is sensible remains open, 
because this method would cause major overhead. As some level of clinical expertise is 
required for assessing whether some tests are useful or not, doctors would need to do 
this to some extent case-by-case. The workload this would cause is major, but whether 
it is still a viable method is open to exploration. 
In any case, this is a factor that is very dependent on the specialty being 
assessed. In cancer care, it is not a major factor in relation to drugs mainly because 
drugs are so highly expensive. In other specialties where drug treatment is less 
expensive, the relative importance of laboratory and imaging expenses might be higher. 
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3.2.3 Overhead expenses 
The costs incurred by performing sponsored clinical trials in general. This includes 
overhead costs from contracts as well as the costs incurred from reporting and related 
tasks that are mandatory for the clinical trials. These overhead expenses can often be 
at least partially paid by the sponsors, but they are still a factor that must be considered 
when assessing the total effect of sponsored clinical trials. 
It is often nigh impossible to separate the overhead costs pertaining to clinical 
trials from those related to other forms of research and teaching at a hospital, as these 
are often done in tandem. For example, HUS has a research director who oversees both 
sponsored clinical trials and purely academic research. However, we can analyze the 
total budgets and distribute overhead costs based on that, if need be.  
3.2.4 Recruitment 
Recruitment of professionals, especially highly skilled ones, is often related to the 
amount of clinical research performed. Thus, a major indirect benefit of conducting 
clinical trials is being able to recruit more skilled professionals. This also has a positive 
feedback loop, as according to our interviews medical companies’ value highly skilled 
individual doctors when choosing the hospital to carry out clinical trials. Thus, actively 
recruiting doctors who have a good reputation in clinical research might increase the 
amount of clinical trials being carried out, which in turn makes recruiting those 
individuals easier. 
However, also nurses and other care personnel are often involved and 
interested in clinical trials. These are not highly experienced individuals and 
competition for them is far lower, but easier recruitment of nurses is a possible benefit 
of clinical trials as well. As there are far more nurses than specialists in a Hospital, the 
different employee groups should all be analyzed in order to assess the impact on 
recruitment. 
3.2.5 Clinical expertise 
 
Research in general has been shown to have a major impact on the clinical expertise of 
personnel (Karma, 2012). This translates to many intangible benefits such as quality of 
care the patients receive. There are also benefits that reach out to the whole country, 
as Käypä hoito -recommendations, the Finnish best practices for healthcare, that are 
used countrywide are also affected by the research done in HUS. Thus, we can assume 
that also sponsored clinical trials have an impact on the clinical expertise of personnel. 
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For this study it is important to note that this factor includes both the clinical 
expertise of nurses as well as the clinical expertise of doctors. These two effects need 
to be measured and considered separately and might have very varying scales. This is 
also a factor that is very difficult to measure. It would be possible to do a comparative 
analysis of nurses involved in clinical trials and those not involved in them and analyze 
the outcomes of treatments, but due to the process having so many variables it would 
be very impractical. Thus, it is most likely best measured with self-assessment, despite 
the inherent issues in self-assessment. 
3.2.6 Clinical practices 
Clinical research performed at HUS has a major impact on the clinical practices at both 
HUS and a national level (Karma, 2012). These practices are most likely also impacted 
by sponsored clinical trials, as they keep the organization up to date with the newest 
advances in medical treatments, thereby enhancing clinical practices. Whether there is 
also an effect of clinical trial practices enhancing how standard care is administered is 
considered in the factor “clinical expertise”. 
Another aspect of clinical practice is whether conducting clinical trials speeds 
up new treatment adoption. This was suggested by both nurses and doctors in 
interviews, with a few possible hypotheses for how the impact works. Firstly, it was 
hypothesized that in general conducting clinical trials requires and teaches skills 
required for adopting new treatments. Thus, it would increase the capability of staff to 
adopt new treatments. Secondly, having given the treatment as part of a clinical trial 
naturally makes it easier to adopt it into standard care later. Whatever the reason, this 
study focuses on determining if such an effect exists via the questionnaire.  
 
3.2.7 Employee well-being 
Performing clinical trials can be a source of employee well-being when organized 
properly. It can give a sense of meaning and be a way of delivering the absolute newest 
and best care available in the world, which increases employee motivation. In general 
personnel expenses are a major factor in all areas of healthcare, and therefore 
employee well-being is a factor that should be considered when discussing total 
benefits of clinical trials.  
However, clinical trials can also decrease employee well-being if they are not 
organized effectively. They might increase the workload of employees so much that it 
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becomes a negative, leading to a decrease in well-being. Thus, it is included in the 
framework on both sides as the effect might be positive or negative.  
3.2.8 Trial effect 
Prior research has found evidence for a trial effect, in which individuals partaking in 
clinical trials seem to benefit from all care more than those not in clinical trials 
(Braunholtz, Edwards, & Lilford, 2001). This is separate from health benefits related to 
newer drugs being available earlier, as a trial effect has also been observed in patient 
groups that receive placebo. Thus, it is included in this framework.  
Whether participating in trials enhances quality of care through e.g. patient 
motivation is open to interpretation. However, for the purposes of this study it is 
enough to assess that such an effect exists, and not pursue the mechanisms related 
further as it is not a part of the scope of this study. 
3.3 Data collection 
In order to use the framework described data was gathered from two main sources: 
accounting systems, and a questionnaire. Some generalized assumptions were also 
made to approximate aspects that were impractical to measure exactly, such as the 
amount of laboratory visits and imaging that were useful for the general care. 
Additionally, data on drug cost avoidance was gathered by creating a data gathering 
spreadsheet that the departments filled with the relevant information either from their 
own archives or by consulting the physicians in charge of the studies. All clinical trials 
between 2012 and 2018 were included, and the following information was gathered: 
physician in charge of the trial, the phase, internal identifier, starting date, end date, 
research nurse, number of patients participating, trial arm treatment, control 
treatment, default treatment if patient was not in a trial and no control treatment 
exists, the full name of the clinical trial. 
Drug cost avoidance used data provided by the hematology and oncology 
departments about the clinical trials and the control treatments that would have been 
used if the patients were not in clinical trials. This data was verified to include all 
relevant trials. This data about clinical trials was then combined with the bookkeeping 
systems of the HUS-pharmacy in order to get the actual savings numbers. As the data 
in general is not in one place it had to be compiled from multiple sources. Three 
methods were used to estimate drug cost avoidance: direct value of drugs received, 
total value of control treatment drugs, and a combination of these in which expensive 
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drugs – defined as accounting for more than 5% of the total value of drugs received – 
were replaced with control treatment drugs.  
Lastly, the bookkeeping of Clinical Research Institute HUCH, the institute 
through which financial transactions concerning clinical trials are performed, was 
analyzed. The relevant projects were selected from a list of all projects, and their 
internal bookkeeping was analyzed to gain visibility into the overheads and potential 
cost savings from laboratory expenses. 
3.3.1 Questionnaire 
Three different questionnaires, shown in the appendices A, B and C, were sent out to 
nurses, residents and specialists, respectively. These were developed based on 
preliminary exploratory interviews conducted with employees in the respective groups. 
The questionnaires were focused on the well-being aspect of individuals and aimed to 
find differences in how clinical trials are perceived in different employee groups. The 
questionnaires were sent to the personnel by their forepersons, in an attempt to 
maximize the response rate. 
The questionnaire was sent out to staff of oncology, hematology and 
rheumatology. Rheumatology was included in the study to increase the number of 
answers, as especially the number of doctors in oncology and hematology departments 
is relatively small. This was done for two main reasons. Firstly, to increase the 
trustworthiness of the questionnaire via increased answer amounts. Secondarily, a 
higher number of respondents makes it harder to distinguish singular doctors from the 
small subset, which was seen as important to ensure trust in the study. Rheumatology 
also conducts sponsored clinical trials, and as such their answers should not diverge 
heavily from those of oncology and hematology 
The questions were in part open and in part on a scale of 1 to 7. As the expected 
number of answers was relatively low the scale of 1 to 7 was chosen to highlight 
opinions that might not be visible on a scale of 1 to 5. The questionnaire was also kept 
as short as possible, only taking some minutes to fill out, in order to increase the 
amount of answers.  
3.4 Data analysis 
As the data is not necessarily directly usable, some analysis is required to reach 
conclusions. This chapter discusses modifying the data available to be suitable for use 
in the framework. 
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3.4.1 Drug cost avoidance 
Three different values for drug cost avoidance were eventually reached in order to form 
a complete picture. Firstly, a theoretical cost savings was calculated, i.e. how much the 
drug treatments outlined in control treatments would have cost if they had been used. 
The control treatments were taken from either the trial protocols, if a control arm 
existed, or from expert opinions from the departments at HUS. Secondly, the total value 
of drugs received as part of clinical trials was calculated. Lastly, a final estimate was 
calculated based on this by replacing highly expensive drugs with control drugs where 
applicable.  Thus, the total value of drug cost avoidance is somewhere in between these 
three numbers. If a control treatment could not be reliably found, the value of the drug 
saving itself was used, as this was likely a case of missing data in our control treatment 
data, so the results would have been possibly skewed if those drugs were disregarded.  
Of these estimates, the higher estimates where highly expensive drugs are 
removed from the total value but not every drug has been analyzed, are the best 
estimate available. In general real processes in hospitals tend to use more expensive 
treatments than theoretical processes, and thus higher estimates are more likely to 
reflect reality. 
 
3.4.2 Laboratory and imaging expenses 
We approximated that half of the laboratory tests and imaging performed in clinical 
trials is useful for the general care, and thus that is the value of laboratory costs 
avoided. This is a rough estimate based on discussions with doctors at HUS, and the real 
value is somewhere between 0% and 100%, with the doctor estimates being between 
20%-50%.   
This number has high uncertainty, but from the discussions with several 
doctors it is evident that some part of the laboratory expenses is saved in any case. As 
the total value of laboratory cost savings is relatively small, the uncertainty here has 
limited impact on the total cost and can be accepted. The impact of laboratory costs is 
possibly higher in other specialties, where drug costs are far lower, but laboratory 
treatments might be used to the same extent. When utilizing this framework to other 
specialties this should be noted and more careful analysis of laboratory expenses is 
required. 
3.4 Data analysis 
 
23 
3.4.3 Employee well-being 
This is the factor that is most difficult to approximate. The potential cost of turnover 
across all of HUS is somewhere around €100 million. This is the starting point from 
which we could approximate the magnitude of potential savings, but at best that would 
be a guess. Thus, this study does not cite a number for the actual savings achievable 
through employee well-being, instead, focusing on whether clinical trials could be a 
major driver of job satisfaction.  
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4 Impact of sponsored clinical trials in HUS 
This chapter finds relevant measurements for the aspects of the framework introduced 
in the previous chapter and uses those measurements to assess the impact of 
sponsored clinical trials in the oncology and hematology wards of Helsinki university 
hospital. The impacts are divided into direct and indirect costs and benefits. 
4.1 Direct costs and benefits 
Firstly, direct costs and benefits were analyzed. These are the effects that are directly 
measurable in monetary value, whether they generate a cashflow or not. It includes 
drug cost avoidance, laboratory and imaging costs as well as overhead costs. 
4.1.1 Drug cost avoidance 
The total drug cost avoidance calculated in the hematology and oncology departments 
in 2017-2018 is shown below in figure 2. The results are in line with prior research on 
the subject, but differ somewhat from the previous approximations used at HUS. This 
is mainly due to the previous approximations being purely based on how much drugs 
are given to HUS without cost. Many of the clinical trials conducted are last line 
treatments, in which the standard of care might not include any drugs. Similarly, often 
very expensive drugs are given to patients who might otherwise only receive standard 
chemotherapy. This is the reason for the large discrepancy between the high value of 
drugs received without cost and the actual drug cost avoidance.  
As the figure below shows, there is high uncertainty related to the exact value 
of drug costs avoided. The figure shows four values related to the value of savings. The 
two lowest values are the estimates reached in this study, one being a more 
conservative estimate where the theorical drug treatment cost of patients enrolled in 
clinical trials that have a control arm of only placebo would have been 0€. This is 
inaccurate, as doctors often overtreat, and the higher estimate takes this into account. 
The highest values are the values of all drugs received in the hematology and oncology 
departments at default wholesale prices. The second highest value is calculated using 
the prices negotiated by HUS, which are generally slightly lower than list prices.   
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Figure 2  Values and estimates of drug cost avoidance at HUS in 2017 and 2018 
The direct cost of drugs provided to HUS in 2018 was €5.1 million, using 
standard prices. The prices negotiated by HUS lower this to €4.5 million due to some 
drugs being less expensive for HUS than in general. Of these, €4.4 million was the value 
of drugs received in hematology and oncology departments. I.e. almost all of the drugs, 
based on value, come to these departments. Same values for 2017 are €4.4 million with 
stock prices, €3.7million with HUS-prices and €3.6 million euros in the oncology and 
hematology departments. The estimated value of drug cost savings was €2.66 million 
in 2018 and €2.74 million in 2017 using a conservative estimate and €3.19 million in 
2018 and €3.57 million in 2017 using a balanced estimate. 
Figure 3 shows the pharmaceutical costs related to clinical trials in 2014-2018. 
A portion of these costs are related to the clinical trial itself, but a substantial portion 
are related to different types of drug handling that is required always, such as preparing 
IV-infusions, which generate cost savings for HUS. The total effect these have is 
relatively small, and because they are so difficult to estimate this study ignores them 
for the cost savings calculations. 
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Figure 3 Pharmaceutical costs related to clinical trials at HUS 2014-2018   
Our data also displays the variance in drug costs, which includes 50 drugs. Of 
these 50 drugs, the four most expensive comprise 50.4% in 2018. Similar results are 
visible in other years, with a small minority of highly expensive drugs being the major 
contributor to the upper bound being so high. Figures 4 and 5 show the distribution of 
all drug cost savings in 2018 and 2017 respectively. They illustrate the 8 most expensive 
drugs comprise slightly over 70% of savings, with the remaining 42 drugs each having a 
small impact in 2018. This effect is even more pronounced in 2017, which also 
showcases the relatively high variance from year to year. The variance outside the most 
expensive drugs is relatively low. 
 
Figure 4 Distribution of drug values in clinical trials by drug in 2018 
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Figure 5 Distribution of drug values in clinical trials by drug in 2017 
4.1.2 Laboratory and imaging expenses 
Laboratory and imaging expenses include both blood tests and similar samples as well 
as imaging such as MRIs. These are often performed on cancer patients, and as such 
their role in the total cost of treatment is not insignificant. The prices used for 
laboratory expenses in this study are the standard prices used by HUS when invoicing 
member municipalities, which reflect the actual costs and do not include excess 
markup. The value of laboratory testing related to clinical trials in HUS was 235 000€ in 
2018 and 198 00€ in 2017 shown in figure 6 below. Based on this, the estimated cost 
savings were 117 500€ and 99 000€ respectively. 
 
Figure 6 Laboratory expenses related to clinical trials at HUS 2014-2018 
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4.1.3 Overhead expenses 
For the overhead costs our data is limited, as Helsinki university hospital changed their 
way of reporting in 2014. Thus, our analysis only covers fiscal years 2014-2018, as the 
data before that is not comparable. Figure 7 below shows the distribution of costs at 
HUCH 2014-2018. As was to be expected, personnel expenses are the majority of all 
costs, varying between 63% and 68% of all costs. No data is available on the distribution 
of these costs beyond these high-level categories.  
 
 
Figure 7 Development of expenses of clinical trials at oncology and hematology 
departments in Euros 2014-2018 
 
 During 2014-2018 the annual income from sponsored clinical trials has been 
5.9% of the revenue. This is the actual net cashflow from performing sponsored clinical 
trials. The average net cashflow annualized 2014-2018 was €106 000.  
4.2 Indirect costs and benefits  
Indirect costs and benefits include all effects that are not easily measurable in short-
term monetary values. This includes recruitment, clinical expertise, clinical practices, 
employee well-being as well as trial effect. These results are based on the 
questionnaires conducted as well as the literature review. Only those questions where 
answers converged are analyzed here, as the conclusion for some questions was clearly 
divergent and thus inconclusive.  
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Overall, 56 responses from nurses, 6 from resident doctors and 18 from 
specialists were received. This translates to response rates of 19%, 7.5% and 15% 
respectively. The number of answers was higher than anticipated and is high enough to 
do conclusions from the data. The differences in responses received are largely equal 
to the differences in general amount of employees, with nurses outnumbering doctors 
by a factor of 2 to 1. Of the nurses 29% had graduated within the last 5 years, and 71% 
were more experienced. 41% of the nurses participated in research, and 59% did not. 
83% of the specialists had been specialists for more than 5 years. 100% of the specialists 
participated in clinical research currently or have in the past, with a median time of 5 
hours per week being used for clinical research. 
4.2.1 Recruitment 
62% of nurses reported that clinical trials do not have an effect on their choice of 
workplace. As there have been no prior studies that would indicate otherwise, we can 
assume that what effect clinical trials might have on recruitment happens through 
other means than direct influence, e.g. by enhancing the employer brand. There might 
be potential to leverage cutting-edge treatments available through clinical trials as a 
recruitment tool, but currently this effect is largely insignificant. The effect clinical trials 
have on workplace brand should also be noted, as even if there is no direct effect the 
employer brand might be affected and there might be an effect through it. 
 50% of specialists reported that clinical research has an impact on their choice 
of workplace, with a further 28% answering neither yes or no. 66% of resident doctors 
reported that clinical trials have an impact on their choice of workplace.  As specialists 
are the most expensive employees to recruit, the actual financial impact that this has 
on recruitment might be relatively high, despite them being a small subgroup of 
employees. Based on the answers this study finds that clinical trials have a limited 
positive effect on recruitment.  
4.2.2 Clinical expertise 
5% of nurses, 0% of specialists and 0% of resident doctors reported that clinical trials 
have a negative impact on the quality of care given at HUS. 22% of nurses, 5% of 
specialists and 16% of resident doctors reported neither negative nor positive effect. 
73% of nurses, 95% of specialists and 84% of resident doctors perceived that clinical 
trials have a positive effect on the quality of care given at HUS. All personnel groups 
also reported positive effects for the speed at which new treatments are taken into use 
as well as in the quality of care they themselves give. 
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Thus, the questionnaire supports the hypothesis that clinical trials increase the 
clinical expertise of nurses. As the answers were so clear, it could be hypothesized that 
the effect is rather substantial, but as the questionnaire did not focus on it more 
research should be conducted before determining the exact effect. However, the data 
heavily suggests that the clinical expertise of nurses is enhanced by conducting clinical 
trials.  
Similarly, the results from doctors and especially specialists converged heavily 
for both the quality of care they themselves give as well as the quality of care given by 
their wards. They also agreed heavily that clinical trials increase the speed at which new 
treatments become a routine part of treatment at HUS. Whether this is due to clinical 
expertise or clinical practices is unclear, but the strong convergence of answers 
suggests a major effect. 
All personnel groups wanted more information about clinical trials conducted 
across their specialty in HUS. 75% of specialists, 94% of nurses and 50% of resident 
doctors wanted more enough information about clinical trials being conducted in HUS. 
The answers reflect a positive approach to clinical trials, and they are largely seen as a 
tool of learning and enhancing care. 
4.2.3 Clinical practices 
No data about the effect of clinical trials on clinical practices was available for this study, 
and an in-depth analysis was out of the scope of this study. Thus, this factor was not 
evaluated. Further research should be conducted if this effect is to be measured. 
However, we can say that this is a positive factor based on the answers received to 
questions related to clinical expertise in our questionnaire, only the size of the effect is 
unknown. The answers for both personal quality of care as well as for the ward quality 
of care, described in the previous chapter, suggest that the effect exists.  
4.2.4 Employee well-being 
According to our questionnaire 55% of nurses nurses felt that cutting-edge treatments 
are an integral part of their jobs at HUS. Simultaneously, only 8% of nurses reported 
unnecessary work due to clinical trials. Combining these with the fact that most nurses 
wanted more information on research at HUS and were willing to participate in clinical 
trials more than currently, it seems likely that clinical trials are a major potential source 
of employee well-being that is already beneficial for HUS but has potential for even 
more. 
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These answers are in stark contrast with those reported by specialist doctors. 
39% of specialists reported that clinical trials cause unnecessary work. Simultaneously, 
78% of specialists agreed strongly or very strongly that they do not have enough time 
for clinical research in their workdays, and 72% of specialists wished to conduct more 
clinical trials despite this. They reported in open questions problems with excess 
workload and a general lack of time was also cited as the main reason for limiting the 
amount of research that doctors conducted. One respondent stated that clinical trials 
do not become a part of the normal work routine at HUS well enough, being a separate 
entity that is done on top of normal clinical work. Simultaneously doctors reported that 
clinical trials cause unnecessary work for them. This may be indicative of the general 
stress that doctors are under, where anything not directly related to clinical work is 
perceived as unnecessary as the normal workload is already very high.  
4.2.5 Trial effect 
We can assume that clinical trials have a beneficial effect for two main reasons. Firstly, 
it has been shown that patients participating in clinical trials receive better care than 
those not in clinical trials (Braunholtz, Edwards & Lilford, 2001). The exact reasons are 
unknown in academic literature, but the phenomenon has been identified. Secondly, 
clinical trials offer care for those patients who might have no choices any more in 
standard care. This can be seen as having a positive effect on the total care given. 
However, this must be analyzed carefully as deciding that clinical trials are beneficial 
due to health reasons quickly leads to questions about the clinical trial process in 
general. Nevertheless, these two effects combined clearly have a positive impact on 
the quality of care given at HUS.  
4.3 Total effects 
Table 3 below outlines all the different aspects considered at HUS, the measurement 
tools used to assess them as well as the estimates reached. Direct and indirect costs 
are separated as the indirect costs are very difficult to conclusively assess in euros. 
Therefore, they are separated and must be interpreted separately.  
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Table 3 Total effects of sponsored clinical trials at HUS 
 
 
Factor Measure 
Finding in HUS oncology and 
hematology 
Direct 
Drug cost 
avoidance 
 
Bookkeeping and 
control treatments 3 to 6 million euros annually 
 
 
Laboratory and 
imaging expenses 
 
Bookkeeping and 
expert assessment of 
the total proportion €100 000 annually 
 
 
 
Monetary 
compensation Bookkeeping 
 
€200 000 - €400 000 annually 
 
 
Overhead 
expenses Bookkeeping 
 
€200 000 annually 
 
Indirect 
 
 
Recruitment 
 
 
 
Questionnaire to staff  
 
 
 
High individual variance, stronger 
effect for specialists but a major 
effect also for nurses 
 
Clinical expertise 
 
Questionnaire to staff 
 
Major effect for both nurses and 
doctors 
 
 
Clinical practices Questionnaire to staff Effect, but extent unknown 
 
Employee 
wellbeing 
Questionnaire to staff 
 
 
Positive for nurses, negative to 
neutral for doctors, major potential 
 
 
Trial effect Academic literature 
 
Minor effect on patient quality of care 
 
 
 
Faster access to 
new treatments 
Not measured 
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In order to set a context for the savings received through indirect effects we 
assess the impact of employee retention. As stated earlier, the total employee turnover 
cost in HUS is roughly €100 million. Based on this, we can approximate that employee 
turnover in hematology and oncology departments could value anywhere from 
€100 000 to up to €1 million. Adding to this the employee satisfaction increase, 
recruitment effects as well as clinical expertise, this study concludes that the indirect 
effects are roughly equal to the direct effects in the case of oncology and hematology 
departments of HUS. This is especially noteworthy because these are the departments 
where drug cost avoidance is highest. In other specialties indirect effects are thereby 
far larger than the direct effects clinical trials have, according to the findings of this 
study.  
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5 Discussion and conclusions 
The main theoretical contribution of this study was to develop a framework that can be 
used to assess all different aspects related to clinical trials. As chapter 4 shows, the 
financial impact of clinical trials is positive for both direct and indirect costs, i.e. it both 
generates a positive cashflow and has a large number of positive effects on the 
organization in general. This chapter discusses both how future research and use should 
refine the framework, as well as the implications that the framework has for HUS. 
5.1 Analysis 
Due to the limited amount of previous literature related to comprehensive clinical trial 
assessment, this study had to develop new measures and some assumptions had to be 
made. This allowed for the creation of the first comprehensive framework that can be 
used to analyze the total impact of clinical trials. Simultaneously, it makes verification 
of the results somewhat more difficult, as there are no previous results to compare to. 
However, for the factors that have been studied before, the findings of this 
study are in line with those reported in previous literature. The major differences are 
in drug cost avoidance calculations. Some previous studies have used a more optimistic 
assessment of the benefit gained from cost-free drugs, using higher values for them 
than this study used. This is especially true for the numbers cited for HUS from 2010. 
However, there are previous studies that used a standard-care -approach and still had 
somewhat differing results. The study by LaFleur et al. (2004) had very similar values 
with a similar methodology, which gives credibility to the findings here. This suggests 
that the differences stem from different countries or hospitals, and not from faults in 
applying the methodology or in the methodology itself.  
Having only a singular point of data, in this case one hospital, might skew the 
results based on the types of clinical trials they carry out. As HUS carries out only tens 
of clinical trials annually, variance is high and a hospital that carries out different types 
of trials might have different numbers. Additionally, it is possible that cancer drug costs 
have changed substantially over the last decade, as the previous studies are from 
around 2010. As the majority of costs come from single, highly expensive drugs, this 
most likely has an impact. 
In general, this study brings light to how major the non-quantifiable effects of 
clinical trials are. This is in line with general findings from other fields, where employee 
motivation especially for highly skilled and specialized individuals has been seen as a 
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major contributor to success of a company for decades. Therefore, it is not surprising 
that clinical trials have major potential for employee well-being and therefore cost 
savings. Based on the discussions and interviews conducted for this study, it is clear 
that employee wellbeing is a major issue at HUS due to the high workload and tight 
budget constraints that specialized healthcare is under. If clinical trials have the 
potential to alleviate the negatives of high workload by increasing employee motivation 
and fulfilment even slightly, they should be explored in-depth.  
As most of the effects found in this study are hard to quantify, they are also 
difficult to get funding for. Finnish hospitals are all public, and as such their funding 
comes from policymakers and their budgets. Therefore, management at hospitals must 
find ways to convince policymakers that investments into employee well-being are 
beneficial through non-quantifiable means. On the other hand, the findings of this 
study clearly show that sponsored clinical trials are a net benefit both indirectly as well 
as in direct cashflow. Thus, it should be relatively easy to convince policymakers that 
investing in clinical trials is a smart choice. 
5.1.1 Direct costs 
As noted in the literature review, drug cost avoidance varies very much based on the 
specialty. Thus, our selected specialties of oncology and hematology have very high 
drug cost reductions, and they are not representative of other specialties. Indeed, these 
two specialties comprise more than 90% of the drugs received at HUS without cost as 
part of sponsored clinical trials. 
What is noteworthy is that the total value of drugs received increased from 
2017 to 2018, but the value calculated here decreased. This phenomenon is explained 
by the fact that four extremely expensive drugs were used more in 2018 than in 2017, 
and the standard care of those patients would have been far less expensive. This 
illustrates why it is so important to monitor these values closely, as pure value of drugs 
received is not always reflective of the value of drug cost avoidance. 
It should also be noted that this value does not include is the possible savings 
from pharmaceutical expenses. As from our data it is impossible to distinguish which 
parts of the pharmaceutical costs are related to dosage and as such would have been 
incurred without the clinical trial, we cannot determine the exact value of those costs.  
Other costs and incomes in the case of Helsinki university hospital are in 
balance, as the pricing of contracts to the sponsors is done so that they cover the 
overhead costs. As we can see the total net income from the clinical trials has been 
roughly 0, as expected. However, we must note that it includes not only overhead costs 
but also some research that is not sponsored. Thus, in order to have a truthful picture 
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of what is the impact of sponsored clinical trials we must consider the account other 
expenses as unrelated. Based on discussions with HUCH, the sponsored clinical trials 
largely cover all overhead expenses, also those incurred by non-sponsored research. 
Thus, we estimate that sponsored clinical trials generate a positive cashflow. 
One aspect to consider about overhead expenses is the extent to which they 
can be influenced and the extent to which they are necessary to fulfill the requirements 
set out by the sponsors of the clinical trials. According to interviews in this study it can 
be estimated that the overhead costs at HUS are largely at a good level, and there is 
minimal room for lowering. As the overhead costs are paid by the sponsors, the 
overhead identified in this study has no effect on the total costs and benefits for HUS. 
Overall, the pure positive cashflow related to sponsored clinical trials is very small in 
comparison to the other positive factors, as it should.  
5.1.2 Indirect costs 
Recruitment answers diverged more than in some other areas, and thus they should be 
analyzed carefully. Answers from different employee groups differed, but there was 
also divergence in answers within the same personnel group. This is most likely because 
the recruitment effect is highly individual, and it is to be expected that for some it is an 
important factor and for some it does not matter at all. Further study on the topic is 
required to understand the effect fully, and to explore different subsets of personnel 
and for which types of employees it is important. Thus, recruitment should never focus 
solely on clinical trials, instead leveraging it where applicable. 
There was major divergence in how specialists saw newest treatments at HUS. 
There is a portion of specialists who do not think that HUS offers the newest treatments 
available through clinical trials. This should be looked at in more detail: is the reason 
lack of clinical trials or somewhere else, and indeed what is the reality. A small, 
divergent set of answers is inconclusive on this issue. It should be explored in more 
depth whether clinical trials could be used as a recruitment tool to find highly skilled 
individuals. 
When discussing employee well-being doctors and nurses have very different 
views. Whatever the reason, in the current state clinical trials are not a source of 
employee well-being for doctors at HUS. However, they could be, as the doctors are 
highly motivated and willing to do research, as it is a key part of the identity of a 
university hospital. Indicative of this is that the only reason cited in the question “What 
are the reasons you have not participated more in clinical trials?”, which was asked if a 
respondent answered yes to wishing they participated more in clinical trials, was a lack 
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of time. These are highly motivated, ambitious individuals, and currently it seems they 
are overburdened and thereby underutilized. 
5.2 Recommendations for improving the framework 
Table 4 below lists recommendations for future research and study in order to improve 
the framework. These should be explored before utilizing the framework again, e.g. in 
HUS, as they could have implications that enhance the precision of the framework. 
 
  Cost effect of personnel costs in clinical trials 
Table 4 Recommendations for future studies to improve the framework 
As this is the first holistic framework for assessing the costs and benefits of clinical trials, 
there is no reference to use to assess if the results are in line with prior results. Drug 
cost avoidance has been studied extensively in the past, and the process utilized here 
is largely an industry standard for assessing it. Thus, the framework improvements 
should focus on finding relevant, easy to use measurement tools for different aspects 
of the framework. 
 Future studies should also make sure that the application of the framework 
gives relevant results that are in line with either expert opinions or previous studies. As 
this is new ground, there is inherent uncertainty and refinement must be made. 
Monitoring the results over the timespan of several years and seeing if changes in the 
workplace and clinical trial conducting methods have effects on the total benefits 
would give more confirmation that the framework is valid.  
The factor this study decided to not incorporate in the framework was patient 
care quality. However, it is fully possible that studies arise in the next few years that 
quantify the effect clinical trials have on patient care. If such findings are made, those 
should be included to the framework. Similarly, some sort of continuous measurement 
Exploring measurement tools for both ease of use and more precision 
 
 
Confirming the findings over longer time periods 
 
Patient care quality assessment and monitoring 
 
Additional factors currently missing 
 
Differences between phases of clinical trials 
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tools for assessing the patient care quality in clinical trials could be used to incorporate 
patient care into the framework. 
The framework might also miss some factors, and as such it should be freely 
appended with new aspects. As the idea of the framework is to create a holistic picture 
that can then be distilled based on the measurements available, all possible aspects 
should be considered and included in it. 
A major area that should be explored in the future is how phase 1 and phase 4 
clinical trials differ from the trials studied here. This would help focus on those phases 
which are most beneficial when taking actions to either increase the amount of clinical 
trials or to enhance their efficiency. Based on the interviews conducted with experts in 
this study it would seem that there is not much difference between phases, but further 
exploration is required to be conclusive. 
It should also be explored in more what is the relation between the time spent 
treating clinical trial patients, i.e. how much time doctors and nurses spend, and the 
reimbursements paid by sponsors. In this study it was assumed that the sum of these 
effects is roughly zero. This is based on the assumption that while sponsors reimburse 
some costs of doctor or nurse visits, often those visits are only needed because the 
patients are partaking in a clinical trial. For practical reasons it was not possible to 
explore this issue further in this study, and thus it should be looked at in the future.  
5.3 Improving the application of the framework at HUS 
The application of the framework had several limitations due to being purely 
retrospective. The suggestions given here should be implemented for the future in 
order to get more precise numbers more easily in subsequent studies into this topic. 
The four improvements focus on the following areas:   
 
 
The laboratory and imaging cost avoidances could be monitored constantly, 
for example by including a note in the reservations and invoices related to those the 
doctor could mark those tests they deem as generally useful, which would make 
monitoring this factor easy over the long run. It would be essentially similar to how 
research visits are monitored now, and if done in an intelligent manner this would not 
− Laboratory and imaging cost monitoring  
− Drug cost avoidance monitoring for all studies 
− Annual surveys to monitor the development of indirect effects 
− Widen the scope to include all specialties with clinical trials 
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cause more than miniscule amounts of extra work for the doctors. Automating the 
monitoring of this factor would give more precise data for decisionmakers in coming 
years at HUS. 
Drug cost avoidance, which HUS has already monitored, should be monitored 
with more precise tools in the future. The main tool for this would be to define a control 
treatment for each study that is representative of the treatment patients would receive 
if they did not partake in a clinical trial. This is a small additional step of bureaucracy, 
but often it is already defined in the research protocols, and doctors need not be too 
precise of it. Both this number, calculated based on theoretical treatments, and the 
total value of drugs received should be monitored, as neither of them is precisely 
correct. Also, a method in which control treatments are only used as a basis for drug 
cost avoidance calculations if the drug is highly expensive is a viable tool that accounts 
for the few, highly expensive trials while minimizing bureaucracy related to reporting. 
This has the benefit of being more precise, as the dosages are real, while being almost 
as accurate as using theoretical control treatments for all clinical trials. 
The qualitative factors are, of course, far more difficult to assess. However, 
annual surveys and similar tools could be used to assess their impact, and especially to 
see increases and decreases in them. Implementing factors from this study into general 
employee well-being questionnaires, if such are used currently, would be an efficient 
method of following relevant measurements. What is most important in qualitative 
factors is consistency. I.e. they should be measured for several years, and trends and 
changes are the important thing, not the absolute values.  
Things such as clinical expertise are influenced by multiple variables ranging 
from individual interests to how the ward an employee works at is led. Thus, it is hard 
to measure which part of that is the result of clinical trials. This could be countered by 
trying to separate those participating in clinical trials from those not participating, and 
if there is a significant difference, we could somewhat quantify the exact effect clinical 
trials have. However, this requires a long period of time, so it must be implemented as 
a standard tool in annual monitoring of employee well-being.  
In general, long-time monitoring of the variables studied in this study is the 
most important thing for the future research into this topic. Incorporating the findings 
of this study into annual monitoring and ensuring that the measurements can be done 
easily and automatically is critical, as only through that can we gain solid insight into 
the total effects. 
Lastly, based on this study it is vital to note that the beneficial effects of 
sponsored clinical trials are not limited to drug costs. Indeed, most effects are outside 
that. This has one major implication: the relative importance of different specialties 
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changes. If drug cost avoidance was the only noteworthy benefit, only those fields 
which have expensive drugs – usually oncology and related specialties – should be 
focused. However, as the benefits are far wider based on this study clinical trials are 
very beneficial also in those specialties where drugs are relatively inexpensive.  
Therefore, all specialties that conduct clinical trials – whether sponsored or not – 
should be included in future studies. 
5.4 Managerial implications 
As we can see from the results conducting sponsored clinical trials is highly profitable 
for university hospitals, and thus should be maximized. This has several implications, 
shown in table 5. The table shows the finding and aim that this study has, as well as 
some tools that this study suggests should be utilized to achieve that goal. On top of 
what is shown here, it should be noted that cutting-edge research is a core 
responsibility of HUS, and clinical trials are a part of that. Indeed, it might be the only 
responsibility HUS has that is profitable and not a cost. 
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Table 5 Managerial implications 
 
Firstly, the hospital should endeavor to maximize the number of trials 
performed at the hospital. This is important not only for the reason that it is profitable, 
but also because being a research hospital is a core part of what makes a university 
hospital a university hospital. The management should try to convince other university 
hospitals and governmental institutions to invest in clinical trials facilitation, in order to 
Aim 
 
Methods 
 
 
Maximizing number 
of clinical trials Optimizing the process for quality and throughput 
 
 
Centralize research nurses to the extent that is possible in 
order to even workload of research nurses 
 
Influencing policymakers to increase the total number of 
trials in Finland 
 
 
Increasing the number of clinical trials, sponsored or not, in 
other specialties 
 
Leverage the 
potential effects on 
nurses 
 
Give nurses more ownership of the clinical trials where 
possible 
 
 
Incorporate more nurses into clinical trials 
 
Increase the well-
being of doctors 
Ensure doctor workloads are reasonable 
 
 
 
Agree that all tasks which can be performed by nurses are 
performed by nurses to decrease the workload on doctors 
 
 
Automate reporting and processing where possible to 
decrease meaningless, tedious work related to clinical trials 
 
Spread knowledge 
more efficiently 
Informal displays of results and ongoing trials at the ward in 
breakrooms etc. 
 
 
Use clinical trials in nurse training 
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increase the number of clinical trials performed in Finland. This kind of co-operation 
and investments on a national level would also increase the number of trials at HUS. 
Simultaneously, HUS should take action to ensure the quality of clinical trials at HUS is 
high, and agreements are met. Ensuring that the output of clinical trials at HUS is of 
high quality is the best method of maximizing the number of trials at HUS in the long 
term. 
Our interviews suggest that combining all of the clinical trial administration 
under one organization might be an efficient method for increasing the quality of the 
trials performed. Ensuring research nurses are available when needed is easier when 
they all share a workload. HUS has already combined administration to HUCH, and it 
might be beneficial to similarly centralize research nurses in order to even the workload 
and ensure throughput stays constant and no single individual becomes a bottleneck 
for the clinical trials. Also the barriers for nurses to partake in clinical trials should be 
lowered in order to increase the flexibility of the staff. The workload is uneven over a 
single year and over multiple years, and some sort of flexibility is required always to 
ensure efficiency. 
If the amount of clinical trials could be increased to the level they were at in 
2007, it would create cost-savings of 3 to 6 million euros annually in HUS alone. When 
considering the cost avoidances received in other institutions too it can be clearly seen 
that even rather expensive investments in order to increase the number of clinical trials 
is financially profitable for the government. Also, the effects shown in this study are not 
the only effects of clinical trials, as they have positive effects in the economy on a larger 
scale too. Thus, based on this study Finland should endeavor to create a unified strategy 
that aims to increase the standing of Finnish hospitals as top-tier clinical trial facilities, 
especially so for all different types of cancer drugs. When discussing benefits on a 
societal level, the relative value of drug cost avoidance increases, as it is a major tool 
that could be used to decrease the costs of healthcare in Finland, which is a hot topic 
at the moment. Thus, on a national level striving to create top-level clinical research in 
fields where new drugs are expensive, mainly in cancer treatment, could decrease the 
costs of healthcare quite substantially. 
Further study should be conducted on the topic of clinical trial drug cost 
avoidance in HUS, as well as in other university hospitals in Finland, outside of the 
oncology and hematology departments. Despite the value of drugs received free of cost 
being relatively small in HUS outside of oncology and hematology, we should be careful 
to not assume that it has to be this way. It could very well be that the oncology and 
hematology departments at HUS have highly skilled individuals and have a good 
reputation, which causes more clinical trials. Further research into the state of other 
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specialties in other Finnish university hospitals could give insight into whether it is 
possible to achieve more cost savings in other specialties too.  
HUS should also take actions to maximize the intangible benefits received from 
clinical trials. The answers to the questionnaire show that nurses feel currently very 
outsiders to clinical trials. It would seem that there is potential for both well-being and 
clinical expertise enhancements if more nurses are integrated to the clinical trial 
process, and it becomes a shared endeavor of the whole organization. There are two 
clearly distinct goals the organization should have. Firstly, more effective and even 
research nurse organization. This means organizing research nurses in such a fashion 
that the workload, which is very uneven over the calendar year, can be effectively 
spread to several nurses and the quality and consistency of clinical trials increases. 
Simultaneously, different types of IT-solutions could be used to increase transparency 
to the patient material available, which lets HUS both give more realistic estimates of 
patient recruitment speed as well as speeds up patient recruitment. HUS already has a 
project underway addressing this, ensuring that project meets its goals and is adopted 
fully is important for effective clinical trials in the future. 
Secondly, clinical trials should be seen as a source of clinical expertise for 
nurses. Lowering the barriers to partake in clinical trials for nurses is very important 
here. This could be achieved by measures such as rotations that include a limited time 
of doing research nurse duties, and similar means. In general, every nurse who is 
interested in clinical trials should be encouraged to participate and to learn the needed 
skills that are required by the medical companies and protocols. This might also 
increase continuity in the long run, as more nurses would have the basic skills for clinical 
trials which might increase both willingness as well as increase the qualifications nurses 
have to do clinical trials. Good Clinical Practices (GCP) could be utilized as a starting 
point for improvement and encouraging more nurses to seek training in them might be 
beneficial. Medical companies could also look into helping nurse training via funding or 
collaboration. This would both benefit the hospitals due to increases in nurse 
satisfaction and skill, and also increase the quality of clinical researches, thereby being 
valuable to also medical companies. 
The well-being of doctors is a major concern for HUS, as it is directly linked to 
employee retention and it is well known that doctors are often under excessive 
workload due to multiple reasons. Thus, HUS should endeavor to make clinical trials – 
which most doctors want to participate in and feel are important – become a more 
integrated part of the work of doctors. Simultaneously, the workload they cause should 
be critically examined in order to ensure that clinical trials do not further burden 
doctors who are already under stress due to workload. Moving all activities related to 
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clinical trials that do not require a doctor to research nurses might be a good way of 
approaching this issue. For example, patient recruitment could be performed more 
cost-effectively by nurses rather than doctors. Whatever the methods, clinical trials are 
a potential source of employee satisfaction for doctors too, but currently its effect is 
perhaps even negative due to workload issues.  
Similarly, recruitment should try to utilize clinical trials as a more effective tool. 
It is well possible that resident doctors as well as nurses could be recruited partially 
thanks to clinical trials, despite current staff not reporting it as a factor in their 
decisions. For specialists this was an important subject, and as such it should be 
leveraged. Recruiting specialists by ensuring they have enough time for clinical trials 
and research might be an effective way of getting highly skilled individuals to work for 
HUS.  
Information should also be spread more effectively. Currently, many nurses 
and doctors do not hear from clinical trials. By improving how much information is 
passed down a sense of meaning and pride in their work could be installed in the 
employees, which could enhance work satisfaction. This could be achieved not only via 
traditional mailing lists and similar communication channels, which are often not very 
effective, but through for example posters and notes on walls displaying the amounts 
and results of clinical trials in HUS. Simultaneously also other types of research should 
be promoted in order to give everyone working in the organization a sense of 
accomplishment for new advances in medicine. Those trials could also be used as part 
of routine staff training whenever applicable, with separate notes given about those 
new treatments that were studied at HUS. All ways of passing on information and 
sharing the accomplishments should be explored, as they are a major source of job 
satisfaction.  
When discussing singular factors that HUS should aim for, the most important 
one is job satisfaction. As cited in the literature review, employee turnover across the 
whole organization has costs of roughly €100 million. If clinical trials can be utilized as 
a tool to increase job satisfaction and thus decrease employee turnover, major cost 
savings could be achieved.  
5.5 Conclusions 
This study had two research questions: how to measure impact of Clinical trials and 
what that impact is in the case of HUS. The literature review found that no 
comprehensive studies exist to assess the impact, and thus a new framework was 
developed based on prior studies and interviews conducted with personnel of HUS. This 
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framework was then used at HUS to assess the impact and to gain evidence of the 
validity of the framework.   
The results are similar to those in previous literature, but more precise, and 
thus they are credible. The framework is the answer to research question one, and 
indicates the complexity of the issue. Research question 2 was studied in chapter 4, 
with total net positive effects of 4-10 million euros. Of this 3-6 million euros are direct 
cost savings, and 2-4 million euros are indirect benefits. 
 
5.6 Limitations 
The framework described in this study aims to be as general as possible, and thus is it 
applicable for all specialties and different types of scenarios where clinical trials are 
done on behalf of a sponsor and some sort of renumeration is paid. However, that 
generality is also a weakness, as it is not very well suited for precise financial analysis. 
As stated earlier, clinical trials are such an extensive issue that their costs and benefits 
are impossible to accurately calculate. 
The application of the framework to the case of hematology and oncology 
departments at HUS has several further limitations that mostly arise from difficulties in 
gathering accurate data. Firstly, the drug cost avoidance cost calculations are 
theoretical, and it is well possible that the patients would have been treated with more 
expensive treatments than this study assumes. However, for the purpose of this study 
it was decided that we use an ideal situation in order to arrive at a lower bound. 
Nevertheless, the results of this study need to be interpreted with thought. 
A major limitation of the study is that it was only carried out at one university 
hospital. Thus, there might be a major skew in the types of clinical trials that are carried 
out, which might skew the effects.  Based on prior research it is clear that oncology has 
the largest cost savings potential, but whether other specialties could have higher cost 
savings than this study suggests is left unanswered as this study does not have valid 
data from other university hospitals to determine which effects are local and which 
generalizable.  
The questionnaire used in this study had relatively limited scope as well as only 
a limited amount of answers were gained for doctors. This is due to the small total 
number of doctors the questionnaire was sent to, in comparison to the much larger 
audience of the nurse questionnaire. When analyzing those answers this study was 
careful to not overstate anything. Deeper analysis into how, exactly, clinical trials could 
impact for example nurse well-being at work is required in order to understand the 
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whole dynamics at work there. The effect of clinical trials is also inseparable from the 
total workload, especially for doctors. Thus, some of the answers might be more due 
to working conditions at the wards or even of the individual doctors rather than the 
clinical trials themselves.  
This study suggests that HUS incorporate questions related to clinical trial in 
their normal annual personnel questionnaires, if such are used, in order to have data 
over multiple years on the effects of clinical trials. A deeper, comparative study should 
also be done to determine the strength of the link between different factors of the 
framework and clinical trials. Despite these limitations, the answers in the 
questionnaire converged strongly, which suggests that they are indicative of the true 
state of things at HUS. 
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